Venetoclax, a B-cell lymphoma 2 (BCL-2) inhibitor, has shown anti-myeloma activity—especially in patients with t(11; 14)—however, it comes with more infectious complications leading to higher mortality in some trials [36,37]. The gene discussed is BCL2; the disease is plasma cell myeloma.